PE17998A1 - Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n` - Google Patents

Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n`

Info

Publication number
PE17998A1
PE17998A1 PE1996000828A PE00082896A PE17998A1 PE 17998 A1 PE17998 A1 PE 17998A1 PE 1996000828 A PE1996000828 A PE 1996000828A PE 00082896 A PE00082896 A PE 00082896A PE 17998 A1 PE17998 A1 PE 17998A1
Authority
PE
Peru
Prior art keywords
compound
bisindolilmaleimidas
bridge
prepare
react
Prior art date
Application number
PE1996000828A
Other languages
English (en)
Inventor
Jr Leonard Larry Winneroski
Margaret Mary Faul
Christine Ann Krumrich
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21725638&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE17998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE17998A1 publication Critical patent/PE17998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIEREN A LOS COMPUESTOS INTERMEDIOS DE FORMULA (I), EN DONDE: R1 ES Br, I o O-TOSILO. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DEL COMPUESTO DE FORMULA (V), QUE COMPRENDE LOS SIGUIENTES PASOS: A) HACER REACCIONAR UN COMPUESTO (I), EN DONDE: R1 ES HIDROXILO, CON PX3, (FENILO)3PX2 o (FENOXI)3PX2, EN DONDE: X ES Br; B) HACER REACCIONAR EL COMPUESTO INTERMEDIO (I) EN DONDE R1 YA SE INDICO, CON HN(CH3)2; ADEMAS, C) HACER REACCIONAR (V) CON CH3SO3H. EL PROCESO CUYO COMPUESTO INTERMEDIO ES (I) EVITA LAS DIFICILES ETAPAS DE PURIFICACION Y ELIMINA LAS IMPUREZAS TOXICAS GENERADAS POR OTROS MEDIOS DE OBTENCION DEL COMPUESTO INHIBIDOR SELECTIVO DE LA PROTEINA QUINASA C, DE FORMULA (V), QUE ES UTIL EN EL TRATAMIENTO DE LA ISQUEMIA O DE LA INFLAMACION, ENTRE OTRAS
PE1996000828A 1995-11-20 1996-11-18 Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n` PE17998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US734595P 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
PE17998A1 true PE17998A1 (es) 1998-04-20

Family

ID=21725638

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000828A PE17998A1 (es) 1995-11-20 1996-11-18 Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n`

Country Status (31)

Country Link
EP (1) EP0776899B1 (es)
JP (2) JP4100708B2 (es)
KR (1) KR100342142B1 (es)
CN (1) CN1066734C (es)
AR (2) AR004719A1 (es)
AT (1) ATE191219T1 (es)
AU (1) AU701659B2 (es)
BR (1) BR9611709A (es)
CA (1) CA2237401C (es)
CO (1) CO4750824A1 (es)
CZ (1) CZ150398A3 (es)
DE (1) DE69607443T2 (es)
DK (1) DK0776899T3 (es)
EA (1) EA000639B1 (es)
ES (1) ES2145978T3 (es)
GR (1) GR3033729T3 (es)
HU (1) HU225716B1 (es)
IL (1) IL124415A (es)
MX (1) MX9803791A (es)
MY (1) MY118946A (es)
NO (1) NO310195B1 (es)
NZ (1) NZ323282A (es)
PE (1) PE17998A1 (es)
PL (1) PL184728B1 (es)
PT (1) PT776899E (es)
TR (1) TR199800876T2 (es)
TW (1) TW371661B (es)
UA (1) UA56145C2 (es)
WO (1) WO1997019080A1 (es)
YU (1) YU49316B (es)
ZA (1) ZA969645B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6300106B1 (en) 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2023192984A1 (en) * 2022-03-31 2023-10-05 4M Therapeutics Inc. N-desmethyl ruboxistaurin as kinase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
RU2147304C1 (ru) * 1993-12-07 2000-04-10 Эли Лилли Энд Компани Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides

Also Published As

Publication number Publication date
ATE191219T1 (de) 2000-04-15
CA2237401C (en) 2003-10-21
CA2237401A1 (en) 1997-05-29
NO982105D0 (no) 1998-05-08
YU49316B (sh) 2005-06-10
PT776899E (pt) 2000-08-31
EP0776899B1 (en) 2000-03-29
ES2145978T3 (es) 2000-07-16
KR19990067600A (ko) 1999-08-25
HUP9901975A2 (hu) 1999-11-29
EP0776899A1 (en) 1997-06-04
NO982105L (no) 1998-05-08
HUP9901975A3 (en) 2000-01-28
IL124415A0 (en) 1998-12-06
HU225716B1 (en) 2007-07-30
EA199800368A1 (ru) 1998-12-24
GR3033729T3 (en) 2000-10-31
JP4100708B2 (ja) 2008-06-11
AR004718A1 (es) 1999-03-10
UA56145C2 (uk) 2003-05-15
CO4750824A1 (es) 1999-03-31
CN1066734C (zh) 2001-06-06
NZ323282A (en) 1999-01-28
DE69607443T2 (de) 2000-08-10
TW371661B (en) 1999-10-11
EA000639B1 (ru) 1999-12-29
DK0776899T3 (da) 2000-07-10
CN1207740A (zh) 1999-02-10
CZ150398A3 (cs) 1998-12-16
PL326753A1 (en) 1998-10-26
AR004719A1 (es) 1999-03-10
IL124415A (en) 2003-11-23
AU701659B2 (en) 1999-02-04
JP2000500496A (ja) 2000-01-18
WO1997019080A1 (en) 1997-05-29
MY118946A (en) 2005-02-28
NO310195B1 (no) 2001-06-05
MX9803791A (es) 1998-09-30
BR9611709A (pt) 1999-02-23
TR199800876T2 (xx) 1998-08-21
YU61096A (sh) 1999-03-04
AU7738896A (en) 1997-06-11
KR100342142B1 (ko) 2002-08-22
ZA969645B (en) 1998-05-18
PL184728B1 (pl) 2002-12-31
DE69607443D1 (de) 2000-05-04
JP2008138006A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE58534T1 (de) 2-pyrimidinyl-l-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
PT100673A (pt) Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos
FI961506A (fi) Distamysiini A -analogit antituumorisina ja antiviraalisina aineina
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
AR001413A1 (es) Compuestos triciclicos de carbamato, utiles para la inhibición de la función de la proteina g y paratratamiento de enfermedades proliferativas.
TR199901578T2 (xx) Klaritromisin form 0 kristali
ES2057899T3 (es) Procedimiento para la preparacion estereoselectiva de derivados de la fenilisoserina.
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
IT1271325B (it) Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
BR8900834A (pt) 1,2,4-triazinodionas substituidas e processo para sua preparacao;compostos intermediarios para as mesmas e processos para sua preparacao;composicoes contra protozoarios parasitarios;processo para o combate dos mesmos;e processo para preparacao de composicoes contra protozoarios parasitarios
PE17998A1 (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n`
ES2177656T3 (es) Derivados de antraciclinona y su utilizacion en el tratamiento de la amiloidosis.
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
PT100672A (pt) Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
ES2169846T3 (es) Compuestos para la absorcion de gases.
BR0009453A (pt) Processo para a preparação de um composto
TR199800210T2 (xx) Didepsipeptid temelli endoparazitisid kompozisyonlar, yeni didepsipeptidler ve bunlar�n �retimi i�in i�lemler.
AR014738A1 (es) Nuevo procedimiento de preparacion de la fexofenadina y compuestos intermediarios
DK0745081T3 (da) Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
ES2145480T3 (es) Amidas de acido carbamoilcarboxilico.
ES538230A0 (es) Procedimiento para la preparacion de nuevos derivados de n-(metoxifenacil)-amina
MX9302429A (es) Nuevas tetralonas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed